CD274 and neoplasm: As the clinical benefit derived from the treatment with EGFR inhibitors is associated with the severity of the skin toxicity in lung and colorectal cancer, we hypothesized that in addition to the well-known cytotoxic effects of EGFR inhibition, a similar modulation of antigen presenting molecules and PD-L1 proteins by EGFR inhibition in tumor cells may be implicated in augmenting anti-tumor immune responses, thus contributing to an additional mechanism of anti-tumor activity in these cancers.